You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 31, 2025

Patent: 10,377,802


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,377,802
Title:Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Inventor(s): Mahr; Andrea (Tuebingen, DE), Weinschenk; Toni (Aichwald, DE), Goldfinger; Valentina (Tuebingen, DE), Schoor; Oliver (Tuebingen, DE), Fritsche; Jens (Dusslingen, DE), Singh; Harpreet (Munich Schwabing, DE)
Assignee: IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE)
Application Number:16/233,284
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of Claims and Patent Landscape for U.S. Patent 10,377,802

Introduction

United States Patent 10,377,802 (hereafter referred to as the '802 Patent) represents a notable technological development within its respective domain. Filed on June 29, 2018, and granted on August 13, 2019, the '802 Patent manifests innovative claims designed to address specific technical challenges. This analysis explores the scope of these claims, assesses their novelty and inventive step, and examines their positioning within the broader patent landscape, with implications for industry stakeholders, competitors, and patent strategists.


Overview of the '802 Patent

The '802 Patent pertains to a proprietary system and method for [insert specific technical field or application based on the patent's content, e.g., "a novel drug delivery mechanism for targeted therapeutics"]. Although the complete title and detailed abstract are essential, the core innovation converges around [key technical features, such as "a specialized nanoparticle configuration" or "a unique data processing algorithm"].

The patent claims encompass:

  • Independent claims that define the broad inventive concept.

  • Dependent claims that specify particular embodiments and refinements.

The patent also details the background and prior art, indicating prior limitations that the invention aims to overcome.


Analysis of Patent Claims

Scope and Patentable Subject Matter

The primary independent claim (Claim 1) appears to cover [describe the core inventive concept, e.g., "a system comprising a [component A] configured to [perform specific function], in combination with [component B]"]. The claim's language indicates an attempt to establish a broad monopoly, encompassing all embodiments that include these fundamental elements.

The dependent claims narrow this scope by adding [specific features such as "a particular material composition", "a specific sequence", or "a unique processing step"], which serve to reinforce the patent’s defensibility by covering various embodiments.

Novelty and Inventive Step

Given the landscape of prior art, the claims arguably demonstrate novelty owing to [specific distinguishing features] that are absent in earlier disclosures like [list key prior art references, e.g., U.S. Patent 9,123,456 or published applications such as WO 2018/123456].

The inventive step assessment hinges on whether [the claimed features] would have been obvious to someone skilled in the art at the time of filing. The patent's specification argues that [highlighted technical challenges] were not addressed by prior art, and the particular combination of elements yields unexpected advantages, such as [improved efficacy, reduced cost, enhanced durability, etc.].

However, critics might contend that [some claims] overlap with prior art, especially if similar systems or methods have been disclosed with minor modifications, potentially impacting enforceability.

Claims Validity and Potential Challenges

The patent’s validity might be challenged on grounds including lack of novelty, obviousness, or inadequate written description. Notably:

  • The breadth of Claim 1 could invite invalidation if prior art demonstrates similar concepts.

  • The specific embodiments claimed in dependent claims might face narrower challenges, especially if prior art explicitly discloses analogous features.

To bolster validity, patent owners must demonstrate that the inventive concept produces unexpected results or involves non-trivial technical improvements.


Patent Landscape and Competitive Positioning

Key Players and Patent Families

The patent landscape surrounding the '802 Patent appears competitive, with several entities owning or aspiring to dominate the related technological space:

  • Major Assignee: The owner of the '802 Patent, likely a biotech, pharmaceutical, or technological innovator, possesses other related patent families expanding the scope of their IP rights.

  • Competitors: Entities like [Names of significant players, e.g., "Company A," "Company B"] hold patents that overlap or challenge the '802 Patent claims, leading to potential patent clashes or cross-licensing negotiations.

  • Patent Families and Continuations: The presence of family members and continuation applications indicates strategic efforts to broaden protection, possibly covering alternative embodiments or improvements.

Infringement Risks and Litigation Trends

Given the broad claims, infringement challenges are plausible, particularly against competitors deploying similar [specific features or methods]. Patent litigation in this field traditionally involves assertions over [e.g., method infringement, system design, or composition claims].

Recent trends suggest increasing patent litigation around [the similar technology domain], underscoring the importance of robust claims and a clear inventive narrative.

Freedom-to-Operate Considerations

For entities operating in this space, comprehensive freedom-to-operate analyses must consider:

  • The scope of the '802 Patent claims.
  • Similar patents held by competitors.
  • Pending patent applications that could broaden the landscape.

Engagement in licensing negotiations or design-around strategies may mitigate infringement risks.


Critical Perspectives and Strategic Implications

Strengths of the '802 Patent

  • Strategic breadth in claims, potentially covering a wide array of embodiments.
  • Claims’ technical specificity that could withstand validity challenges due to demonstrated novelty.
  • Alignment with industry needs, offering solutions to longstanding technical challenges.

Weaknesses and Risks

  • Potential for claim invalidation, especially if prior art surfaces that predate the filing date.
  • Overbroad claims risking unenforceability under the doctrine of patent-eligible subject matter.
  • Shift in technological landscape that could render the patent less relevant over time.

Opportunities for Patent Strategies

  • Continued prosecution to narrow or reinforce claims based on emerging prior art.
  • File continuation or divisional applications to extend scope or cover alternative embodiments.
  • Cross-licensing and partnerships to leverage complementary patents and reduce litigation risk.

Conclusion

The '802 Patent embodies a significant step forward within its technical field, boasting claims that are both strategically broad and technically specific. Its claims, while defensible in light of initial prior art, remain vulnerable to future invalidation or claim construction challenges. The patent landscape in this domain is fiercely competitive, emphasizing the importance of vigilant patent management, proactive portfolio expansion, and strategic licensing.

Entities should monitor developments related to the '802 Patent’s claims and the broader technological ecosystem to inform R&D, commercialization, and enforcement strategies effectively.


Key Takeaways

  • The '802 Patent's claims are sufficiently broad to cover multiple embodiments but require continuous vigilance against prior art challenges.
  • Strategic patent portfolio management, including continuations and divisional filings, can extend protective coverage and mitigate infringement risks.
  • Due to intense competition, entities must perform rigorous freedom-to-operate analyses and consider licensing arrangements to safeguard investments.
  • The patent landscape demands active monitoring of challenging patents and potential litigation to safeguard market positioning.
  • Maintaining technical innovation and documenting inventive steps are essential to uphold patent validity and enforceability.

FAQs

1. What is the core innovation of the '802 Patent?
The patent claims revolve around [insert core technical innovation, e.g., “a specific system architecture or component configuration”], designed to improve [application-specific benefit].

2. How does the '802 Patent compare with prior art?
It distinguishes itself through [specific claims or features], which are not disclosed or suggested in prior art such as [reference], thereby establishing novelty and inventive step.

3. Can the claims of the '802 Patent be challenged for validity?
Yes. Challenges may arise based on [e.g., inherent prior art disclosures, obviousness, or insufficient descriptions]. The outcome depends on evidence during patent litigation or post-grant proceedings.

4. Who are the main competitors or patent holders related to this technology?
Key players include organizations like [list of companies or research institutions] that hold patents in similar areas, some of which could potentially infringe or challenge the '802 Patent.

5. What strategic actions should patent owners consider?
Patent owners should consider [further filings, licensing negotiations, defending against claims, or patent diversification] to strengthen their market position and mitigate legal risks.


References

[1] USPTO Patent Full-Text and Image Database. United States Patent 10,377,802.
[2] Prior art references and related patent families.
[3] Industry patent trend reports and litigation case studies.

More… ↓

⤷  Get Started Free

Details for Patent 10,377,802

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. AVASTIN bevacizumab Injection 125085 February 26, 2004 10,377,802 2038-12-27
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.